• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by ABVC BioPharma Inc. (Amendment)

    2/13/24 7:59:14 PM ET
    $ABVC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVC alert in real time by email
    SC 13G/A 1 sch13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     

     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No. 1)*
     

     
    ABVC BioPharma, Inc.
     
     
    (Name of Issuer)
     

     
    Common Stock, par value $0.001 per share
     
     
    (Title of Class of Securities)
     

     
    00091F304
     
     
    (CUSIP Number)
     

     
    December 31, 2023
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [ ]            Rule 13d-1(b)
    [x]            Rule 13d-1(c)
    [ ]            Rule 13d-1(d)
    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Fund II LP
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    770,000
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    770,000
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    770,000(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
    12
    Type of Reporting Person (See Instructions)
    PN
     
    (1) The reporting person’s ownership consists of (i) 146,097 shares of common stock, (ii) 529,166 warrants to purchase shares of common stock (the “Warrants”), and (iii) up to 1,926,706 shares of common stock issuable to the reporting person pursuant to a convertible security entered into between Lind Global Fund II and ABVC BioPharma, Inc. (the “Convertible Security”); however, due to the exercise limitations of the Warrants and the conversion limitations on the Convertible Security, the reporting person’s beneficial ownership has been limited to 770,000 shares in the aggregate.
    (2) The Warrants and the Convertible Security each include a provision limiting the holder’s ability to exercise the Warrants or convert the Convertible Security if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
    Lind Global Partners II LLC
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    Delaware

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    770,000
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    770,000
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    770,000(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
    12
    Type of Reporting Person (See Instructions)
    OO
     
    (1) The reporting person’s ownership consists of (i) 146,097 shares of common stock, (ii) 529,166 Warrants, and (iii) shares of common stock issuable to the reporting person pursuant to the Convertible Security; however, due to the exercise limitations of the Warrants and the conversion limitations of the Convertible Security, the reporting person’s beneficial ownership has been limited to 770,000 shares in the aggregate.
    (2) The Warrants and the Convertible Security each include a provision limiting the holder’s ability to exercise the Warrants or convert the Convertible Security if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

    1
    Names of Reporting Persons.
    I.R.S. Identification Nos. of above persons (entities only)
     
    Jeff Easton
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a)            [ ]
     
    (b)            [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States

    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5  Sole Voting Power
     
    770,000
    6  Shared Voting Power
     
    0
    7  Sole Dispositive Power
     
    770,000
    8  Shared Dispositive Power
     
    0

    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
    770,000(1)
     
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
     
     
    11
    Percent of Class Represented by Amount in Row (9)*
     
    9.9%(2)
     
    12
    Type of Reporting Person (See Instructions)
     
    IN
     
    (1) The reporting person’s ownership consists of (i) 146,097 shares of common stock, (ii) 529,166 Warrants, and (iii) shares of common stock issuable to the reporting person pursuant to the Convertible Security; however, due to the exercise limitations of the Warrants and the conversion limitations of the Convertible Security, the reporting person’s beneficial ownership has been limited to 770,000 shares in the aggregate.
    (2) The Warrants and the Convertible Security each include a provision limiting the holder’s ability to exercise the Warrants or convert the Convertible Security if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.


    Item 1.
    (a)
    Name of Issuer
     
     
    ABVC BioPharma, Inc.

    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    44370 Old Warm Springs Blvd.
    Fremont, CA 94538

    Item 2.
    (a)
    Name of Person Filing
     
     
    This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
     
    •   Lind Global Fund II LP, a Delaware limited partnership;
    •   Lind Global Partners II LLC, a Delaware limited liability company; and
    •   Jeff Easton, an individual and a citizen of the United States of America.
     
    Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    Jeff Easton, the managing member of Lind Global Partners II LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    The address of the principal business office for each of the Reporting Persons is:
     
    444 Madison Ave, Floor 41
    New York, NY 10022
     
    (c)
    Citizenship
     
     
    See Row 4 of cover page for each Reporting Person.
     
    (d)
    Title of Class of Securities
     
     
    Common Stock, $0.001 par value per share
     
    (e)
    CUSIP Number
     
     
    00091F304

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    Not applicable.
    Item 4.
    Ownership
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a)
    Amount Beneficially Owned
     
     
     See Row 9 of cover page for each Reporting Person.
     
    (b)
    Percent of Class
     
     
    See Row 11 of cover page for each Reporting Person.
     

    (c)
    Number of shares as to which such person has:
     
     
    (i)
    sole power to vote or to direct the vote
       

    See Row 5 of cover page for each Reporting Person.
     
     
    (ii)
    shared power to vote or to direct the vote
       
     
    See Row 6 of cover page for each Reporting Person.
     
     
    (iii)
    sole power to dispose or to direct the disposition of
       

    See Row 7 of cover page for each Reporting Person.
     
     
    (iv)
    shared power to dispose or to direct the disposition of
       
     
    See Row 8 of cover page for each Reporting Person.
     

    Item 5.  Ownership of Five Percent or Less of a Class
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following □.
    Item 6.  Ownership of More than Five Percent on Behalf of Another Person
    Not applicable.
    Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
    Not applicable.
    Item 8.
    Identification and Classification of Members of the Group
    Not applicable.
    Item 9.
    Notice of Dissolution of Group
    Not Applicable.
    Item 10.
    Certification
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

    Exhibits
    Exhibit
    99.1            Joint Filing Agreement by and among the Reporting Persons


    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 13, 2024

    LIND GLOBAL FUND II LP
       
    By:
     
    Lind Global Partners II LLC
     
     
    its General Partner
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    LIND GLOBAL PARTNERS II LLC
       
    By:
     
    /s/ Jeff Easton
    Name:
     
    Jeff Easton
    Title:
     
    Managing Member
     
    JEFF EASTON
     
    By:
     
    /s/ Jeff Easton

    Get the next $ABVC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ABVC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ABVC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ABVC BioPharma Seeks to Revolutionize Mental Health Treatment With a Safe Prozac Alternative, Boasting a MADRS Score Reduction of -13.21

      FREMONT, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company focused on innovative treatments in ophthalmology, CNS (central nervous system), and oncology/hematology, today announced in response to the discontinuation of Prozac[1] due to increasing concerns around side effects, ABVC believes its ABV-1504, which has the API, "Radix Polygala", known as Polygala tenuifolia Willd or PDC-1421, can fill this void in the mental health market. With a robust formulation designed to reduce adverse effects, PDC-1421 promises to offer a safer and more effective solution for patients dealing with MDD and ADHD[2]. ABVC's ABV-1504 has c

      12/19/24 8:30:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC BioPharma Secures $200,000 in First Cash Licensing Payment From Oncology Products Partner, Totaling $546,000 From Three Partners

      FREMONT, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company advancing therapeutic solutions in ophthalmology, CNS (central nervous system), and oncology/hematology, announced the receipt of a $200,000 cash payment from OncoX BioPharma Inc. ("OncoX") as part of its strategic licensing agreement for certain oncology-related products; this payment marks the first installment of $5 million in potential licensing fees from OncoX. With this payment, the total accumulated cash payment ABVC has received from its three strategic partners for licensing various ABVC products is $546,000. ABVC and its subsidiaries BioLite Inc. and R

      12/11/24 6:30:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones

      ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in incomeReceived Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024 FREMONT, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, is pleased to announce its financial results and key operational highlights for the third quarter ended September 30, 2024. Key Financial and Operational Highl

      11/14/24 9:00:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    SEC Filings

    See more
    • Amendment: ABVC BioPharma Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Financial Statements and Exhibits

      8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

      5/14/25 4:30:10 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: ABVC BioPharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

      5/14/25 8:30:35 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: ABVC BioPharma Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

      8-K/A - ABVC BIOPHARMA, INC. (0001173313) (Filer)

      5/6/25 4:30:28 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by ABVC BioPharma Inc.

      SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

      11/14/24 7:33:18 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by ABVC BioPharma Inc. (Amendment)

      SC 13G/A - ABVC BIOPHARMA, INC. (0001173313) (Subject)

      2/13/24 7:59:14 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by ABVC BioPharma Inc.

      SC 13G - ABVC BIOPHARMA, INC. (0001173313) (Subject)

      8/7/23 4:01:26 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Jiang Shuling claimed ownership of 7,908,805 shares

      3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)

      7/12/22 5:01:09 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider An Chihliang claimed ownership of 13,334 shares

      3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)

      3/31/22 11:31:22 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Sakamoto Norimi

      3 - ABVC BIOPHARMA, INC. (0001173313) (Issuer)

      12/10/21 4:19:06 PM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Financials

    Live finance-specific insights

    See more
    • ABVC Acquires $2.96 Million Worth of Land in Asia with Stocks Priced at $3.50 per Share

      FREMONT, CA, Feb. 08, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in Oncology/Hematology, Neurology, and Ophthalmology, announced today that it signed a definitive agreement to acquire real estate in Taoyuan City, Taiwan. The acquisition of real estate assets, estimated at approximately $2.96 million via an equity transfer of $3.50 per share, is to develop plant factories for ABVC's botanical pipeline strategically; ABVC hopes the property will ultimately be used as an integrated platform for the global development of the Asian healthcare business and the medical, pha

      2/8/24 9:17:05 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ABVC
    Leadership Updates

    Live Leadership Updates

    See more
    • ABVC BioPharma Enters Definitive Agreement with Licensing Income Worth $467M and Royalties Up to $200M

      FREMONT, CA, Nov. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – ABVC BioPharma, Inc. (NASDAQ:ABVC) ("Company"), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, announced today that it entered into a global licensing definitive agreement with AiBtl BioPharma Inc. (AiBtl) for the Company's CNS drugs with the indications of MDD (Major Depressive Disorder) and ADHD (Attention Deficit Hyperactivity Disorder) (the "Licensed Products"). The agreement has the potential of licensing income worth $467M and royalties up to $200M. The Licensed Products for MDD and ADHD, owned by ABVC and its su

      11/16/23 10:05:12 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ABVC BioPharma, Inc. Announces New CEO as It Targets Further Growth

      FREMONT, CA, June 26, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire -- ABVC BioPharma, Inc. (NASDAQ:ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in oncology/hematology, CNS, and ophthalmology, today announced the appointment of Dr. Uttam Yashwant Patil (Dr. Uttam) as the new Chief Executive Officer (CEO). Dr. Uttam is very familiar with ABVC and their subsidiaries, because of his role as Chief Operating Officer & Chief Scientific Officer of BioKey, Inc., a GMP-certified facility owned by ABVC that provides its clients with integrated pharmaceutical services, including early-phase product development, formulation development, analytical development & d

      6/26/23 8:30:00 AM ET
      $ABVC
      Biotechnology: Pharmaceutical Preparations
      Health Care